12 March 2026
The Medannex team was delighted to receive the award for Innovation in Drug Discovery at Scotland’s Life Sciences Awards 2026, held in Glasgow.
In a highly competitive category, the expert judging panel recognised Medannex’s achievements following the presentation of compelling clinical data at the European Society of Medical Oncology Congress in October 2025.
Initial data from the first-in-human study of MDX-124, the first therapeutic designed to target annexin-A1, demonstrated encouraging clinical activity in patients with advanced cancer. The therapy was shown to control disease progression and shrink tumours, while maintaining a favourable safety profile with no significant adverse effects observed.
Following the successful establishment of the Recommended Phase 2 Dose, the clinical programme is now progressing into tumour-specific arms. Patient enrolment is underway, beginning with biliary tract cancer, with additional tumour types planned for evaluation over the course of the year.
Medannex would like to thank all of the patients and clinicians involved in the study.